Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA

Bibliography

• Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 2010;115(1-2):22-7
   PubMed Web of Science ®Google Scholar
• Rodriques Coura J, De Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97(9):3-24
   PubMedGoogle Scholar
• Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010;115(1-2):55-68
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B, Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7(2):157-63
   PubMed Web of Science ®Google Scholar
• Schoijet AC, Miranda K, Girard-Dias W, A Trypanosoma cruzi phosphatidylinositol 3-kinase (TcVps34) is involved in osmoregulation and receptor-mediated endocytosis. J Biol Chem 2008;283(46):31541-50
   PubMed Web of Science ®Google Scholar
• Schoijet AC, Miranda K, Soares Medeiros CC, Defining the role of a FYVE domain in the localization and activity of a cAMP phosphodiesterase implicated in osmoregulation in Trypanosoma cruzi. Mol Microbiol 2011;79(1):50-62
   PubMed Web of Science ®Google Scholar
• King-Keller S, Li M, Smith A, Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease. Antimicrob Agents Chemother 2010;54(9):3738-45
   PubMed Web of Science ®Google Scholar
• Montalvetti A, Bailey BN, Martin MB, Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001;276(36):33930-7
   PubMed Web of Science ®Google Scholar
• Szajnman SH, Bailey BN, Docampo R, Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorg Med Chem Lett 2001;11(6):789-92
   PubMed Web of Science ®Google Scholar
• Szajnman SH, Montalvetti A, Wang Y, Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 2003;13(19):3231-5
   PubMed Web of Science ®Google Scholar
• Montalvetti A, Fernandez A, Sanders JM, Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol Chem 2003;278(19):17075-83
   PubMed Web of Science ®Google Scholar
• Garzoni LR, Waghabi MC, Baptista MM, Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004;23(3):286-90
   PubMed Web of Science ®Google Scholar
• Bouzahzah B, Jelicks LA, Morris SA, Risedronate in the treatment of Murine Chagas' disease. Parasitol Res 2005;96(3):184-7
   PubMed Web of Science ®Google Scholar
• Richards MR, Lowary TL. Chemistry and biology of galactofuranose-containing polysaccharides. ChemBioChem 2009;10(12):1920-38
   PubMed Web of Science ®Google Scholar
• Kleczka B, Lamerz AC, Van Zandbergen G, Targeted gene deletion of Leishmania major UDP-galactopyranose mutase leads to attenuated virulence. J Biol Chem 2007;282(14):10498-505
   PubMed Web of Science ®Google Scholar
• Bontempi E, Martinez J, Cazzulo JJ. Subcellular localization of a cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 1989;33(1):43-7
   PubMed Web of Science ®Google Scholar
• Cazzulo JJ, Cazzulo FM, Martinez J, Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta 1990;1037(2):186-91
   PubMed Web of Science ®Google Scholar
• Engel JC, Doyle PS, Hsieh I, Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998;188(4):725-34
   PubMed Web of Science ®Google Scholar
• Murta AC, Persechini PM, Padron TDS, Structural and functional identification of GP57/51 antigen of Trypanosoma cruzi as a cysteine proteinase. Mol Biochem Parasitol 1990;43(1):27-38
   PubMed Web of Science ®Google Scholar
• Gauthier JY, Chauret N, Cromlish W, The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008;18(3):923-8
   PubMed Web of Science ®Google Scholar
• Beaulieu C, Isabel E, Fortier A, Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease. Bioorg Med Chem Lett 2010;20(24):7444-9
   PubMed Web of Science ®Google Scholar
• Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003;90(Supp 1):S19-39
   PubMedGoogle Scholar
• Canavaci AM, Bustamante JM, Padilla AM, In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis 2010;4(7):e740
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Tarleton RL. Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov 2011;16(6):633-44
   Google Scholar
• Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T. cruzi Replication. Available from: http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1885; [Cited]
   Google Scholar
• Buckner FS, Verlinde CL, La Flamme AC, Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 1996;40(11):2592-7
   PubMed Web of Science ®Google Scholar
• Bettiol E, Samanovic M, Murkin AS, Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis 2009;3(2):e384
   PubMed Web of Science ®Google Scholar
• Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 2008;14(5):542-50
   PubMed Web of Science ®Google Scholar
• Hospital Universitari Vall d'Hebron Research Institute. Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole (CHAGASAZOL). ClinicalTrials.goc Identifier NCT01162967. Available from: http://clinicaltrials.gov/ct2/show/NCT01162967; [Cited]
   Google Scholar
• Romanha AJ, Castro SL, Soeiro Mde N, In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz 2010;105(2):233-8
   PubMed Web of Science ®Google Scholar
• Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987;81(5):755-9
   PubMed Web of Science ®Google Scholar
• Laucella SA, Perez Mazliah D, Bertocchi G, Changes in Trypanosoma cruzi-specific immune responses following treatment: surrogate markers of treatment efficacy. Clin Infect Dis 2009;49(11):1675-84
   PubMed Web of Science ®Google Scholar